Can Dash Bio’s $30m automation bet break one of drug development’s slowest bottlenecks?
Dash Bio’s $30 million Series A backs automated bioanalysis expansion, but validation, scale and sponsor adoption will determine its impact.
Medical Devices & Diagnostics
Pharma & Biotech
Cogent advances third bezuclastinib FDA submission after APEX pivotal trial results
Cogent’s bezuclastinib NDA for advanced systemic mastocytosis is backed by APEX data showing 65% ORR and deep KIT-driven disease marker reductions.